Vai al contenuto principale
xMedica

NCT07606066ClinicalTrials.gov

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient…

Osservazionale2150 partecipanti ricercati76 centri7 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2026-05-26; recorded start 2026-05-06
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1019 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 71 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,150 participants (target), run at 76 sites, across 7 countries.

How this score is built
  • Enrolment33/40

    2,150 participants (target)

  • Site count21/25

    71 sites

  • Country count12/15

    7 countries

  • Planned duration5/10

    Planned over about 11 months

  • Sponsor scale10/10

    AstraZeneca has led 991 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

Patologie

  • Type 2 Diabetes

Idoneità

Idoneità
SessoTutti
Età18 YearsNessun massimo
Volontari saniNo
Metodo di campionamentoNON_PROBABILITY_SAMPLE

Popolazione dello studio

Adults with Type 2 Diabetes

Idoneità come riportata nel registro

Inclusion Criteria: * Participants must be ≥ 18 years of age at the time of signing the ICF. * Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World Health Organization or local diagnostic standards, inadequately managed with: 1. Lifestyle management alone, AND/OR 2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF. * Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required. * Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis. Exclusion Criteria: * Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol). * Diagnosed with Type 1 diabetes mellitus. * Known pregnancy at the time of visit or having the intention to become pregnant.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioOsservazionale
FaseNon indicato nella scheda del registro
AssegnazioneNon indicato nella scheda del registro
Modello di interventoNon indicato nella scheda del registro
Finalità principaleNon indicato nella scheda del registro
MascheramentoNon indicato nella scheda del registro
Arruolamento2150 partecipanti ricercati

Sponsor e collaboratori

  • AstraZeneca Sponsor

Bracci e interventi

  • Participants with Type 2 Diabetes

    Participants with Type 2 Diabetes

Interventi

  • Altro Procedure: assessment

    The approximate volume of blood required is 2 mL

Esiti misurati

  1. Esito primario

    Patient demographics

    Summary statistics

    Orizzonte temporale Visit 1 (Single day)

  2. Esito primario

    Medical and surgical history

    Summary statistics

    Orizzonte temporale Visit 1 (Single day)

  3. Esito primario

    Concomitant medication

    Summary statistics

    Orizzonte temporale Visit 1 (Single day)

  4. Esito primario

    HbA1c levels

    Summary statistics

    Orizzonte temporale Visit 1 (Single day)

  5. Esito secondario

    Referral to ongoing or future T2DM study.

    Number of participants with high likelihood of meeting eligibility criteria in ongoing or future T2DM studies, for referral to those studies.

    Orizzonte temporale Visit 1 (Single day)

Date

Date
Data di inizio6 maggio 2026 (effettiva)
Conclusione primaria31 marzo 2027 (stimata)
Conclusione31 marzo 2027 (stimata)
Prima pubblicazione26 maggio 2026 (effettiva)
Ultimo aggiornamento25 agosto 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltamarzo 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

19 centri stanno reclutando

Brazil

Brazil
StrutturaCittàStato o regioneStato
Research SiteBarretosNon ancora in reclutamento
Research SiteBrasíliaNon ancora in reclutamento
Research SiteCampinasSão PauloNon ancora in reclutamento
Research SiteCuritibaParanáIn reclutamento
Research SiteFortalezaCearáNon ancora in reclutamento
Research SiteNatalRio Grande do NorteNon ancora in reclutamento
Research SitePorto AlegreRio Grande do SulNon ancora in reclutamento
Research SiteRio de JaneiroNon ancora in reclutamento
Research SiteSão José dos CamposSão PauloNon ancora in reclutamento
Research SiteSão PauloSão PauloNon ancora in reclutamento
Research SiteSão PauloSão PauloNon ancora in reclutamento

Hungary

Hungary
StrutturaCittàStato o regioneStato
Research SiteBudapestIn reclutamento
Research SiteBudapestNon ancora in reclutamento
Research SiteBudapestIn reclutamento
Research SiteBudapestHUIn reclutamento
Research SiteBudapestHUIn reclutamento
Research SiteDebrecenHUNon ancora in reclutamento
Research SiteSalgótarjánNon ancora in reclutamento
Research SiteSzegedHUNon ancora in reclutamento
Research SiteSzolnokNon ancora in reclutamento
Research SiteZalaegerszegIn reclutamento

India

India
StrutturaCittàStato o regioneStato
Research SiteBangaloreKarnatakaNon ancora in reclutamento
Research SiteBelagaviKarnatakaNon ancora in reclutamento
Research SiteBelagaviKarnatakaNon ancora in reclutamento
Research SiteCalicutKeralaNon ancora in reclutamento
Research SiteChennaiTamil NaduNon ancora in reclutamento
Research SiteCoimbatoreTamil NaduNon ancora in reclutamento
Research SiteDelhiNew DelhiNon ancora in reclutamento
Research SiteGunturAndhra PradeshNon ancora in reclutamento
Research SiteGuwahatiAssamNon ancora in reclutamento
Research SiteIndoreMadhya PradeshNon ancora in reclutamento
Research SiteJaipurRajasthanNon ancora in reclutamento
Research SiteKochiKeralaNon ancora in reclutamento
Research SiteKolkataWest BengalNon ancora in reclutamento
Research SiteLucknowUttar PradeshNon ancora in reclutamento
Research SiteMumbaiMaharashtraNon ancora in reclutamento
Research SiteNagpurMaharashtraNon ancora in reclutamento
Research SitePuneMaharashtraNon ancora in reclutamento
Research SitePuneMaharashtraNon ancora in reclutamento
Research SiteThiruvananthapuramKeralaNon ancora in reclutamento

Malaysia

Malaysia
StrutturaCittàStato o regioneStato
Research SiteBatu CavesSelangorRitirato
Research SiteKuala LumpurWilayah Persekutuan Kuala LumpNon ancora in reclutamento
Research SitePutrajayaNon ancora in reclutamento
Research SiteSerembanNegeri SembilanIn reclutamento
Research SiteSeri ManjungPerakNon ancora in reclutamento

Poland

Poland
StrutturaCittàStato o regioneStato
Research SiteBialystokPodlaskie VoivodeshipIn reclutamento
Research SiteCzęstochowaSilesian VoivodeshipNon ancora in reclutamento
Research SiteKielceŚwiętokrzyskie VoivodeshipNon ancora in reclutamento
Research SiteKrakowMalopolskaNon ancora in reclutamento
Research SiteLodzŁódź VoivodeshipIn reclutamento

Nella scheda del registro sono indicati altri 26 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 25 agosto 2026

    Centro aggiunto

    5 sites added (76 total)

    7176